VAL-PAMIDRONATE DISODIUM 9 MG
PAMIDRONATE DISODIUM : 9 MG · DIN 02382032 · VALEO PHARMA INC
Health Canada status: CANCELLED POST MARKET
What is VAL-PAMIDRONATE DISODIUM?
VAL-PAMIDRONATE DISODIUM 9 MG contains PAMIDRONATE DISODIUM : 9 MG. It is listed in the Health Canada Drug Product Database under DIN 02382032, held by VALEO PHARMA INC, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as cancelled post market, status dated 17-Jul-2015. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02382032 |
|---|---|
| Brand name | VAL-PAMIDRONATE DISODIUM |
| Generic / active ingredient | PAMIDRONATE DISODIUM : 9 MG |
| Manufacturer | VALEO PHARMA INC |
| Strength | 9 MG |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | M05BA03 PAMIDRONIC ACID |
| AHFS class | 92:24.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 17-Jul-2015 |
| Original market date | 2012-11-01 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code M05BA03 PAMIDRONIC ACID. 8 of 23 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| PAMIDRONATE DISODIUM FOR INJECTION | 3 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 02244550 |
| PAMIDRONATE DISODIUM FOR INJECTION | 3 MG | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02246597 |
| PAMIDRONATE DISODIUM FOR INJECTION | 6 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 02244551 |
| PAMIDRONATE DISODIUM FOR INJECTION | 6 MG | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02246598 |
| PAMIDRONATE DISODIUM FOR INJECTION | 9 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 02244552 |
| PAMIDRONATE DISODIUM FOR INJECTION | 9 MG | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02246599 |
| PAMIDRONATE DISODIUM OMEGA 6 MG/ML | 6 MG | SOLUTION | OMEGA LABORATORIES LIMITED | MARKETED | DIN 02249677 |
| PAMIDRONATE DISODIUM OMEGA 9 MG/ML | 9 MG | SOLUTION | OMEGA LABORATORIES LIMITED | MARKETED | DIN 02249685 |
| AREDIA | 60 MG | POWDER FOR SOLUTION | NOVARTIS PHARMACEUTICALS CANADA INC | CANCELLED POST MARKET | DIN 02059770 |
| AREDIA 30MG | 30 MG | POWDER FOR SOLUTION | NOVARTIS PHARMACEUTICALS CANADA INC | CANCELLED POST MARKET | DIN 02059762 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.